Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Oct
29
Today In Oncology
TIL Therapy Plus Pembrolizumab for Advanced Melanoma
Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction
Sacituzumab Tirumotecan Extends PFS OS in Advanced Recurrent Endometrial Cancer
Expert Histopathology and Molecular Testing Improve Diagnosis of Ambiguous Cutaneous Melanocytic Tumors
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo